PTC Therapeutics Reports Positive Huntington's Study Results, Novartis Starts Phase 3

Key Facts

PTC Therapeutics announced positive 24-month interim results from its PIVOT-HD study, showing that votoplam slowed Huntington's disease progression by 52% at a 10 mg dose. Despite these clinical milestones and the initiation of a global Phase 3 study by Novartis, shares of PTCT tumbled sharply on Wednesday. The company's stock, which trades on the NASDAQ, faced significant selling pressure following the data release. While the study highlighted a favorable safety profile and dose-dependent benefits, the market reaction remained decidedly negative. Investors are currently weighing the promising long-term clinical data against the immediate bearish price action. The partnership with Novartis remains a focal point as the drug candidate moves toward potential commercialization despite the recent volatility.